Research progress of Alectinib in the treatment of non-small cell lung cancer
10.11904/j.issn.1002-3070.2016.01.016
- VernacularTitle:Alectinib在非小细胞肺癌治疗中的研究进展
- Author:
Xia PAN
- Publication Type:Journal Article
- Keywords:
Non-small cell lung carcinoma;
EML4-ALK;
Drug resistance;
Alectinib;
Target therapy
- From:Practical Oncology Journal
2016;30(1):75-79
- CountryChina
- Language:Chinese
-
Abstract:
Recently,targeted therapy plays an important role in the treatment of non-small cell lung cancer.Crizotinib,the first generation of anaplastic lymphoma kinase( ALK) tyrosine kinase inhibitor,has been ap-proved for the treatment of ALK-rearranged NSCLC in the US since 2011.However,the crizotinib therapy is ef-fective only in the early stage of treatment.After a long time treatment,therapy resistance will follow because of the emerging second mutation of the tumor cell.In recent years,as the second generation of anaplastic lymphoma kinase tyrosine kinase inhibitor, alectinib has been approved in Japan for the treatment of ALK -rearranged NSCLC patients.Thus,research progress of Alectinib for NSCLC therapy is summarized in this article.
